---
title: "上海医药获得新加坡市场批准用于抗凝药物"
description: "上海医药获得新加坡抗凝药物的市场批准"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/276822785.md"
published_at: "2026-02-25T03:07:08.000Z"
---

# 上海医药获得新加坡市场批准用于抗凝药物

> 上海医药获得新加坡抗凝药物的市场批准

### Related Stocks

- [512010.CN - 易方达沪深300医药ETF](https://longbridge.com/zh-CN/quote/512010.CN.md)
- [601607.CN - 上海医药](https://longbridge.com/zh-CN/quote/601607.CN.md)
- [159849.CN - 招商中证生物科技主题ETF](https://longbridge.com/zh-CN/quote/159849.CN.md)
- [159929.CN - 汇添富中证医药卫生ETF](https://longbridge.com/zh-CN/quote/159929.CN.md)
- [159859.CN - 天弘国证生物医药ETF](https://longbridge.com/zh-CN/quote/159859.CN.md)
- [159506.CN - 富国恒生港股通创新药及医疗保健ETF](https://longbridge.com/zh-CN/quote/159506.CN.md)
- [516930.CN - 生物科技ETF基金](https://longbridge.com/zh-CN/quote/516930.CN.md)
- [159892.CN - 华夏恒生生物科技ETF(QDII)](https://longbridge.com/zh-CN/quote/159892.CN.md)
- [159992.CN - 创新药](https://longbridge.com/zh-CN/quote/159992.CN.md)
- [159615.CN - 南方恒生生物科技ETF(QDII)](https://longbridge.com/zh-CN/quote/159615.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/zh-CN/news/276886600.md) |
| China Medical System Gets China Acceptance for Atopic Dermatitis Drug | China Medical System Gets China Acceptance for Atopic Dermatitis Drug | [Link](https://longbridge.com/zh-CN/news/276718382.md) |
| China's Jiuyuan Genetic seeks approval for Wegovy biosimilar | Jiuyuan Genetic Biopharmaceutical has applied for approval to sell its biosimilar version of Wegovy in China, ahead of a | [Link](https://longbridge.com/zh-CN/news/276994337.md) |
| China CDE Grants GenFleet’s GFH375 Breakthrough Therapy Designation for KRAS G12D NSCLC | GenFleet Therapeutics (Shanghai) Inc. has received Breakthrough Therapy Designation from China's Center for Drug Evaluat | [Link](https://longbridge.com/zh-CN/news/277376970.md) |
| CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab | CStone Pharmaceuticals has received UK approval for its lung cancer drug, sugemalimab, as a monotherapy for adult patien | [Link](https://longbridge.com/zh-CN/news/276549711.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。